Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis
April 25, 2023 07:59 ET
|
Lyra Therapeutics
WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the...
Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 29, 2023 16:06 ET
|
Lyra Therapeutics
-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in...
Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer
February 27, 2023 07:59 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the...
Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients
February 06, 2023 07:56 ET
|
Lyra Therapeutics
-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra’s Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients -- WATERTOWN, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) --...
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2023 18:42 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing therapies for the localized...
Lyra Therapeutics to Present at Upcoming Investor Conferences
November 09, 2022 08:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing novel, integrated drug and delivery solutions for the...
Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022 16:01 ET
|
Lyra Therapeutics
-- Company Prioritizing ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Chronic Rhinosinusitis (CRS); Study Remains on Track, with Full Enrollment Anticipated mid-2023 -- -- Company to Manufacture...
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
September 21, 2021 07:00 ET
|
Lyra Therapeutics
LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis...
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
September 20, 2021 07:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...
Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
September 13, 2021 07:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...